ECSP13012665A - Nueva forma de administracion de inhibidor de encefalinasa - Google Patents

Nueva forma de administracion de inhibidor de encefalinasa

Info

Publication number
ECSP13012665A
ECSP13012665A ECSP13012665A ECSP13012665A EC SP13012665 A ECSP13012665 A EC SP13012665A EC SP13012665 A ECSP13012665 A EC SP13012665A EC SP13012665 A ECSP13012665 A EC SP13012665A
Authority
EC
Ecuador
Prior art keywords
new
encephalinasa
administration form
inhibitor administration
inhibitor
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Xavier Ligneau
Jean Stéphane JULIEN
Marc Maury
Philippe Robert
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of ECSP13012665A publication Critical patent/ECSP13012665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con una nueva formulación de un inhibidor de encefalinasa, tal como racecadotril o dexecadotril, con el proceso para la preparación del mismo y con el uso del mismo en el tratamiento de diarrea.
ECSP13012665 2010-12-10 2013-06-06 Nueva forma de administracion de inhibidor de encefalinasa ECSP13012665A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306397A EP2462922A1 (en) 2010-12-10 2010-12-10 New form of administration of enkephalinase inhibitor

Publications (1)

Publication Number Publication Date
ECSP13012665A true ECSP13012665A (es) 2013-08-30

Family

ID=45092498

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012665 ECSP13012665A (es) 2010-12-10 2013-06-06 Nueva forma de administracion de inhibidor de encefalinasa

Country Status (32)

Country Link
US (1) US9439853B2 (es)
EP (2) EP2462922A1 (es)
JP (1) JP5847192B2 (es)
KR (1) KR101837685B1 (es)
CN (1) CN103338749B (es)
AP (1) AP3787A (es)
AU (1) AU2011340500B2 (es)
BR (1) BR112013014388A2 (es)
CA (1) CA2820835C (es)
CO (1) CO6731092A2 (es)
CY (1) CY1123056T1 (es)
DK (1) DK2648696T3 (es)
EA (1) EA022730B1 (es)
EC (1) ECSP13012665A (es)
ES (1) ES2791710T3 (es)
HR (1) HRP20200555T1 (es)
HU (1) HUE049273T2 (es)
IL (1) IL226775A (es)
LT (1) LT2648696T (es)
MA (1) MA34724B1 (es)
ME (1) ME03769B (es)
MX (1) MX354858B (es)
NZ (1) NZ611597A (es)
PL (1) PL2648696T3 (es)
PT (1) PT2648696T (es)
RS (1) RS60197B1 (es)
SG (1) SG191068A1 (es)
SI (1) SI2648696T1 (es)
SM (1) SMT202000229T1 (es)
TN (1) TN2013000239A1 (es)
UA (1) UA111835C2 (es)
WO (1) WO2012076691A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
EP2866789B1 (en) 2012-06-28 2018-08-01 Johnson & Johnson Consumer Inc. Racecadotril lipid compositions
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
PT2866802T (pt) * 2012-06-28 2016-09-05 Johnson & Johnson Consumer Inc Composições líquidas racecadotril
CN105848643A (zh) * 2013-12-23 2016-08-10 强生消费者公司 消旋卡多曲组合物
EP2918268A1 (en) 2014-03-10 2015-09-16 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
ES2555484T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril
CN105125477A (zh) * 2015-08-19 2015-12-09 黑龙江佰彤儿童药物研究有限公司 一种含消旋卡多曲的药物制剂及制备方法
IT201700099690A1 (it) 2017-09-06 2019-03-06 Abiogen Pharma Spa Composizione per l’integrazione di calcio

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
DK1294372T3 (da) 2000-06-23 2005-09-19 Bioprojet Soc Civ Törpulverformulering der omdanner racecadotril
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
EP1563848A1 (en) * 2004-02-12 2005-08-17 Bioprojet New combinations of an anti-emetic agent and an enkephalinase inhibitor
WO2007102171A2 (en) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
CN101103960B (zh) * 2006-07-14 2010-12-08 海南盛科生命科学研究院 一种含有消旋卡多曲的干混悬剂及其制备方法
TW201014830A (en) 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Also Published As

Publication number Publication date
MA34724B1 (fr) 2013-12-03
DK2648696T3 (da) 2020-05-04
AU2011340500B2 (en) 2016-10-20
CA2820835A1 (en) 2012-06-14
AP2013006971A0 (en) 2013-07-31
JP5847192B2 (ja) 2016-01-20
MX2013006492A (es) 2013-11-01
JP2014503512A (ja) 2014-02-13
PL2648696T3 (pl) 2020-07-27
UA111835C2 (uk) 2016-06-24
ES2791710T3 (es) 2020-11-05
ME03769B (me) 2021-04-20
HRP20200555T1 (hr) 2020-07-24
PT2648696T (pt) 2020-05-13
HUE049273T2 (hu) 2020-09-28
KR20130124335A (ko) 2013-11-13
AU2011340500A1 (en) 2013-06-27
MX354858B (es) 2018-03-23
BR112013014388A2 (pt) 2016-09-27
EP2462922A1 (en) 2012-06-13
EP2648696A1 (en) 2013-10-16
NZ611597A (en) 2015-01-30
EA201300688A1 (ru) 2014-11-28
US20130331423A1 (en) 2013-12-12
US9439853B2 (en) 2016-09-13
WO2012076691A1 (en) 2012-06-14
LT2648696T (lt) 2020-05-11
AP3787A (en) 2016-08-31
KR101837685B1 (ko) 2018-03-12
TN2013000239A1 (en) 2014-11-10
EA022730B1 (ru) 2016-02-29
CA2820835C (en) 2019-01-08
CN103338749B (zh) 2017-04-26
EP2648696B1 (en) 2020-02-19
CO6731092A2 (es) 2013-08-15
SMT202000229T1 (it) 2020-07-08
IL226775A (en) 2017-09-28
CN103338749A (zh) 2013-10-02
CY1123056T1 (el) 2021-10-29
SG191068A1 (en) 2013-07-31
SI2648696T1 (sl) 2020-07-31
RS60197B1 (sr) 2020-06-30

Similar Documents

Publication Publication Date Title
CO6731092A2 (es) Nueva forma de administración de inhibidor de encefalinasa
MX394441B (es) Una formulación a base de besifloxacina para usarse en el tratamiento del acné resistente a fármacos
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
MX2015016406A (es) Formulacion de revestimiento para madera.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
MX391858B (es) Compuestos terapeuticamente activos y sus metodos de uso
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
CO6811867A2 (es) Cannabinoides para uso en el tratamiento del dolor neuropático
MX2017006149A (es) Composiciones para el cuidado personal con dos fases beneficas.
MX2015016783A (es) Inhibidores de moleculas pequeñas de fibrosis.
CO7141434A2 (es) Nueva forma de dosificación formulación de abediterol
GT201500247A (es) Imidazopiridazinas sustituidas
CR20150211A (es) Compuestos diméricos
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
PH12014502860A1 (en) Racecadotril liquid compositions
CR20150096A (es) Formulaciones de trans-clomifeno y usos de los mismas
ES2421956A1 (es) Nueva forma cristalina de sulfato de sitagliptina
PE20141584A1 (es) Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina